Completed NA INTERVENTIONAL NCT00211601

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) (C-PHONE)

Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis

Sponsor: Merck Sharp & Dohme LLC

Conditions Chemotherapy Induced Nausea and Vomiting

Interventions Disease Management Assessment

Updated 6 times since 2017 Last updated: Apr 30, 2015 Started: Aug 31, 2004 Primary completion: Dec 31, 2005 Completion: Dec 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00211601, this NA trial focuses on Chemotherapy Induced Nausea and Vomiting and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jun 2022 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Jun 2022 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.